TAHL CINDY 4

What Happened

• Cindy Tahl, Chief Legal and Compliance Officer of Fate Therapeutics (FATE), exercised options on May 6, 2026 to acquire a total of 166,664 shares (122,220 + 44,444) for aggregate cash paid of roughly $207,996. The filings also show simultaneous dispositions of the same 166,664 derivative shares at $0 (typical in net exercises/withholding).

Key Details

• Transaction date: 2026-05-06; Form 4 filed 2026-05-07.
• Exercise details:
  • 122,220 shares exercised at $1.32 each — reported value $161,330.
  • 44,444 shares exercised at $1.05 each — reported value $46,666.
• Simultaneous dispositions: 122,220 and 44,444 derivative shares disposed at $0 (total disposed = 166,664).
• Transaction code: M (option exercise/conversion).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • F1: The 122,220-option tranche vests monthly over 36 months starting Jan 1, 2025 (fully vested Jan 1, 2028) subject to continued service.
  • F2: The 44,444-option tranche vests monthly over 36 months starting Jan 1, 2026 (fully vested Jan 1, 2029) subject to continued service.
• Filing timeliness: No late-filing indication in the supplied data.

Context

• For retail investors: this was an option exercise (code M). The report shows both acquisition and simultaneous disposition of the same derivative shares — a common pattern when options are exercised and shares are net-settled or withheld to cover exercise cost/taxes (the filing itself does not state the exact reason). Exercises indicate the insider converted vested options into shares; whether shares were retained or effectively used to satisfy obligations is not disclosed here.